Research Analysts Offer Predictions for WST Q1 Earnings

West Pharmaceutical Services, Inc. (NYSE:WST) – Stock analysts at Zacks Research increased their Q1 2026 earnings per share (EPS) estimates for shares of West Pharmaceutical Services in a research report issued to clients and investors on Thursday, March 5th. Zacks Research analyst Team now forecasts that the medical instruments supplier will earn $1.66 per share for the quarter, up from their previous forecast of $1.64. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $6.62 per share. Zacks Research also issued estimates for West Pharmaceutical Services’ Q2 2026 earnings at $1.98 EPS, Q3 2026 earnings at $2.05 EPS, Q4 2026 earnings at $2.17 EPS, FY2026 earnings at $7.85 EPS, Q1 2027 earnings at $1.82 EPS, Q4 2027 earnings at $2.51 EPS, FY2027 earnings at $8.79 EPS and FY2028 earnings at $10.29 EPS.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, February 12th. The medical instruments supplier reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.21. The business had revenue of $805.00 million for the quarter, compared to analysts’ expectations of $795.70 million. West Pharmaceutical Services had a return on equity of 17.90% and a net margin of 16.06%.The business’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.82 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS.

A number of other equities analysts have also recently issued reports on WST. Jefferies Financial Group restated a “buy” rating and issued a $295.00 price objective on shares of West Pharmaceutical Services in a research report on Tuesday, February 10th. Wall Street Zen raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research note on Saturday, December 20th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of West Pharmaceutical Services in a research report on Friday, January 9th. Barclays cut their price objective on West Pharmaceutical Services from $325.00 to $265.00 and set an “equal weight” rating on the stock in a research report on Friday, February 13th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $315.00 target price on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $314.56.

West Pharmaceutical Services Stock Up 0.6%

Shares of NYSE WST opened at $245.92 on Friday. The firm’s fifty day moving average is $253.72 and its 200 day moving average is $262.03. West Pharmaceutical Services has a 52 week low of $187.43 and a 52 week high of $322.34. The company has a quick ratio of 2.34, a current ratio of 3.02 and a debt-to-equity ratio of 0.06. The company has a market cap of $17.71 billion, a price-to-earnings ratio of 36.22, a PEG ratio of 2.59 and a beta of 1.17.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in WST. Elyxium Wealth LLC purchased a new stake in West Pharmaceutical Services in the fourth quarter worth $25,000. CYBER HORNET ETFs LLC bought a new position in shares of West Pharmaceutical Services in the 2nd quarter worth about $25,000. Bayban purchased a new position in West Pharmaceutical Services during the 4th quarter valued at about $27,000. Private Trust Co. NA boosted its stake in West Pharmaceutical Services by 156.4% during the fourth quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock worth $28,000 after acquiring an additional 61 shares in the last quarter. Finally, DV Equities LLC purchased a new stake in West Pharmaceutical Services in the fourth quarter worth about $28,000. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services declared that its board has authorized a share buyback plan on Tuesday, February 17th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the medical instruments supplier to reacquire up to 5.6% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its shares are undervalued.

West Pharmaceutical Services Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 6th. Shareholders of record on Wednesday, April 29th will be issued a $0.22 dividend. The ex-dividend date is Wednesday, April 29th. This represents a $0.88 annualized dividend and a yield of 0.4%. West Pharmaceutical Services’s dividend payout ratio (DPR) is 12.96%.

West Pharmaceutical Services News Summary

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Zacks Research raised several near‑term and multi‑year EPS estimates for WST (notable changes: FY2026 to $7.85 from $7.52, FY2027 to $8.79 from $8.51, and FY2028 to $10.29) and upgraded multiple quarter forecasts (Q1–Q4 2026 and Q1/Q4 2027). The firm keeps a “Strong‑Buy” rating — a coordinated set of upgrades that tends to support investor conviction and share demand. MarketBeat: West Pharmaceutical Services
• Neutral Sentiment: These revisions largely align with West’s own FY2026 guidance range (7.85–8.20 EPS), so part of the move may reflect confirmation of management direction rather than a surprise beat. Analysts’ models can change and represent expectations, not guarantees.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.